Paxos Therapeutics is a biotechnology company focused on developing novel therapeutics for neurodegenerative diseases, with an emphasis on tauopathies including Progressive Supranuclear Palsy (PSP).
- Tau-Targeting Therapies: Developing small molecules targeting pathological tau protein
- Protein Aggregation Inhibitors: Blocking tau misfolding and aggregation
- Neuroprotective Approaches: Protecting neurons from tau-induced toxicity
- PAX-101: Lead program in preclinical development for tauopathies
- Research programs targeting additional neurodegenerative mechanisms
The company's approach focuses on:
- Inhibiting tau aggregation pathways
- Promoting tau clearance mechanisms
- Protecting neurons from tau-mediated cytotoxicity
- Academic research partnerships
- Potential clinical trial networks for PSP
- Based in Cambridge, Massachusetts (biotech hub)
- Focus on precision medicine approaches for neurodegenerative diseases
This page provides information about Paxos Therapeutics.